20.500.12556/RUL-133624 Cannabinoids and hormone receptor-positive breast cancer treatment Breast cancer (BC) is the most common cancer in women worldwide. Approximately 70–80% of BCs express estrogen receptors (ER), which predict the response to endocrine therapy (ET), and are therefore hormone receptor-positive (HR+). Endogenous cannabinoids together with cannabinoid receptor 1 and 2 (CB1, CB2) constitute the basis of the endocannabinoid system. Interactions of cannabinoids with hypothalamic–pituitary–gonadal axis hormones are well documented, and two studies found a positive correlation between peak plasma endogenous cannabinoid anandamide with peak plasma 17β-estradiol, luteinizing hormone and folliclestimulating hormone levels at ovulation in healthy premenopausal women. Do cannabinoids have an effect on HR+ BC? In this paper we review known and possible interactions between cannabinoids and specific HR+ BC treatments. In preclinical studies, CB1 and CB2 agonists (i.e., anandamide, THC) have been shown to inhibit the proliferation of ER positive BC cell lines. There is less evidence for antitumor cannabinoid action in HR+ BC in animal models and there are no clinical trials exploring the effects of cannabinoids on HR+ BC treatment outcomes. Two studies have shown that tamoxifen and several other selective estrogen receptor modulators (SERM) can act as inverse agonists on CB1 and CB2, an interaction with possible clinical consequences. In addition, cannabinoid action could interact with other commonly used endocrine and targeted therapies used in the treatment of HR+ BC. hormone receptor breast cancer cannabinoids treatment CBD THC estrogen cannabinoid receptor hormonski receptor rak dojke kanabinoidi true false true Angleški jezik Slovenski jezik Članek v reviji 2021-12-06 11:58:21 2021-12-06 11:58:27 2022-09-13 03:51:42 0000-00-00 00:00:00 2020 0 0 12 str. iss. 3, art. 525 Vol. 12 2020 0000-00-00 Zaloznikova Objavljeno apc 0000-00-00 0000-00-00 0000-00-00 616-006 2072-6694 10.3390/cancers12030525 34716889 RAZ_Dobovisek_Luka_2020.pdf RAZ_Dobovisek_Luka_2020.pdf 1 26555D7A0CFCD0CAFC2AED2FCF7A90C8 0a5fcc4ee5a684e7458f8aa4871caea90bbb632ccc51b75f92e913f027c50ed5 10f39a10-5684-11ec-abdb-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=151835 https://www.mdpi.com/2072-6694/12/3/525 1 570717bd-5683-11ec-abdb-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=151834 Medicinska fakulteta 0 0 0